From the Departments of ∗Nuclear Medicine

†Hematology, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Received for publication December 5, 2023; revision accepted January 17, 2024.

Y.Z. and X.W. contributed equally to this work.

Conflicts of interest and sources of funding: This work was supported in part by the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-003) and the National High Level Hospital Clinical Research Funding (2022-PUMCH-D-002). The authors have reported that they have no relationships relevant to the contents of this article to disclose.

Correspondence to: Li Huo, MD, Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1# Shuaifuyuan, Dongcheng District, Beijing, China 100730. E-mail: [email protected].